[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

2024131 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Oncology

Volume 25, Issue 5, pp. 563-571

Field-Weighted Citation Impact: 54.39